Shots:  

• The P-III Jupiter-02 Study involve assessing of Toripalimab vs PBO in combination with + Gemcitabine/ Cisplatin for 1L treatment of 289 patients with recurrent or metastatic NPC
• The study resulted in meeting its pre-specified 1EPs of PFS and has expanded the PFS. The company will submit the BLA to NMPA & other countries
• Toripalimab is a PD-1 mAB and has received NMPA’s approval for metastatic melanoma on Dec 17- 2018- in China

­ Ref: PRNewswire | Image: Junshi